1,2-Benzisoxazole compounds: a patent review (2009 – 2014)

Bibliography

• Gualtieri F, Giannella M. 1,2-Benzisoxazole. The Chemistry of Heterocyclic Compounds: Isoxazoles, Part Two 1999;49:1-122
   Google Scholar
• Yevich JP, New JS, Smith DW, et al. Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents. J Med Chem 1986;29:359-69
   PubMed Web of Science ®Google Scholar
• Jain M, Kwon C-H. 1,2-Benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. J Med Chem 2003;46:5428-36
   PubMed Web of Science ®Google Scholar
• Uno H, Kurokawa M, Masuda Y, et al. Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J Med Chem 1979;22:180-3
   PubMed Web of Science ®Google Scholar
• Priya BS, Swamy BSN, Rangappa KS, et al. Synthesis and characterization of novel 6-fluoro-4-piperidinyl-1,2-benzisoxazole amides and 6-fluoro-chroman-2-carboxamides: antimicrobial studies. Bioorg Med Chem 2005;13:2623-8
   PubMed Web of Science ®Google Scholar
• Shutske GM, Setescak LL, Allen RC, et al. [(3-Aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series. J Med Chem 1982;25:36-44
   PubMed Web of Science ®Google Scholar
• Nuhrich A, Varache-Lembege M, Renard P, et al. Synthesis and inhibitory effects on platelet aggregation of 3-(2-thienyl)- and 3-(1-imidazolyl)-1,2-benzisoxazole derivatives. Eur J Med Chem 1994;29:75-83
   Web of Science ®Google Scholar
• Barcelo M, Ravina E, Varela MJ, et al. Potential atypical antipsychotics: synthesis, binding affinity and SAR of new heterocyclic bioisosteric butyrophenone analogues as multitarget ligands. Med Chem Commun 2011;12:1194-200
   Web of Science ®Google Scholar
• Strupczewski JT, Allen RC, Gardner BA, et al. Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles. J Med Chem 1985;28:761-9
   PubMed Web of Science ®Google Scholar
• Lamani RS, Shetty NS, Kamble RR, et al. Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-b][1,3,4]thiadiazole derivatives. Eur J Med Chem 2009;44:2828-33
   PubMed Web of Science ®Google Scholar
• Pigini M, Giannella M, Gualtieri F, et al. Analogs with a 1,2-benzisoxazole nucleus of biologically active indole derivatives. III. Tryptamine and gramine isosteres. Eur J Med Chem 1975;10:29-32
   Web of Science ®Google Scholar
• Pigini M, Giannella M, Gualtieri F, et al. Analogs with a 1,2-benzisoxazole nucleus of biologically active indole derivatives. IV. 5-Hydroxytryptamine isosteres. Eur J Med Chem 1975;10:33-6
   Web of Science ®Google Scholar
• Ferraris D, Duvall B, Ko YS. Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J Med Chem 2008;51:3357-9
   PubMed Web of Science ®Google Scholar
• Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Exp Opin Drug Metab Toxicol 2008;4:493-506
   PubMed Web of Science ®Google Scholar
• Risperidone label information FDA Web Site. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020272s073,020588s062,021444s048lbl.pdf [Last accessed on 25 February 2015]
   Google Scholar
• Paliperidone label information FDA Web Site. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf [Last accessed on 25 February 2015]
   Google Scholar
• Paliperidone palmitate label information FDA Web Site. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf [Last accessed on 25 February 2015]
   Google Scholar
• Iloperidone label information FDA Web Site. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022192s013lbl.pdf [Last accessed on 25 February 2015]
   Google Scholar
• Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1081-90
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Levander S, Kjaersdam Telleus G, et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 2015;131:185-96
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9
   PubMed Web of Science ®Google Scholar
• Jiangsu Nhwa Pharmaceutical Co., Ltd. 2,6-Diketone-piperazin-(piperidine) derivative and application thereof. CN103242219
   Google Scholar
• Chen Y, Xu X, Liu X, et al. Synthesis and evaluation of a series of piperidine-2,6-dionepiperazine (piperidine) derivatives as multireceptor atypical antipsychotics. Arch Pharm(Weinheim) 2012;345:859-69
   PubMed Web of Science ®Google Scholar
• Huazhong University of Science and Technology, Jiangsu Nhwa Pharmaceutical Co., Ltd. Benzopyrone derivative and use thereof. WO136147;2012
   Google Scholar
• Chen Y, Wang SL, Xu XQ, et al. Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics. J Med Chem 2013;56:4671-90
   PubMed Web of Science ®Google Scholar
• Huazhong University of Science and Technology Jiangsu Nhwa Pharmaceutical Co., Ltd. Alicyclic[c]benzopyrone derivative and use thereof. WO017071; 2013
   Google Scholar
• Chen Y, Lan Y, Wang SL, et al. Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics. Eur J Med Chem 2014;74:427-39
   PubMed Web of Science ®Google Scholar
• Jiangsu Nhwa Pharmaceutical Co., Ltd and Huazhong University of Science and Technology. [1,3,4]Oxadiazole derivative and application thereof. WO130183; 2012
   Google Scholar
• Jiangsu Nhwa Pharmaceutical Co., Ltd. Flavonoid derivatives and use thereof. WO146553; 2014
   Google Scholar
• F. Hoffmann-La Roche AG. Ether derivatives. WO052899;2008
   Google Scholar
• F. Hoffmann-La Roche AG. Dual modulators of 5-HT2A and D3 receptors. WO013212; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Piperazine D3 and 5-HT2a receptor modulators. WO031735; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors. WO034646; 2010
   Google Scholar
• Adamed, Ltd. Arylosulfonamides for the treatment of CNS diseases. WO035123; 2012
   Google Scholar
• Kolaczkowski M, Marcinkowska M, Bucki A, et al. Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem 2014;57:4543-57
   PubMed Web of Science ®Google Scholar
• Kolaczkowski M, Mierzejewski P, Bienkowski P, et al. A.ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonist activity: pharmacological profile and potential therapeutic utility. Br J Pharmacol 2014;171:973-84
   PubMed Web of Science ®Google Scholar
• Adamed Ltd. Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases. WO001505; 2013
   Google Scholar
• Adamed Ltd. Sulphonamide derivatives of benzylamine for the treatment of CNS diseases. WO140347; 2013
   Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255-70
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV. Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters. US6077843
   Google Scholar
• Carter NJ. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. Drugs 2012;72:1137-60
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson Web Site. Available from: http://www.investor.jnj.com/releasedetail.cfm?releaseid=883843 [Last accessed on 26 February 2015]
   Google Scholar
• Ascendis Pharma A/S. Carrier linked paliperidone prodrugs. WO042450; 2011
   Google Scholar
• Ascendis Pharma A/S Web Site. 2014. Available from: http://www.ascendispharma.com/technology [Last accessed on 26 February 2015]
   Google Scholar
• Ascendis Pharma A/S. Polymeric hyperbranched carrier-linked prodrugs for diagnosis and therapy. WO024048; 2013
   Google Scholar
• Ascendis Pharma A/S. High-loading water-soluble carrier-linked prodrugs for diagnosis and therapy. WO024047; 2013
   Google Scholar
• Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta) for maintenance treatment in patients with bipolar disorder. Exp Rev Neurother 2010;10:1637-58
   PubMed Web of Science ®Google Scholar
• Alkermes, Inc. Prodrugs for the treatment of schizophrenia and bipolar disease. WO084850; 2011
   Google Scholar
• Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-79
   PubMed Web of Science ®Google Scholar
• Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of D2 receptor, and/or 5-HT2A receptor. US159033; 2010
   Google Scholar
• Protia, LLC. Deuterium-enriched risperidone. US212976; 2011
   Google Scholar
• Sumitomo-Dainippon Pharma Co., Ltd. N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof. WO111875; 2011
   Google Scholar
• Sumitomo-Dainippon Pharma Co., Ltd. A cycloalkane derivative. WO002103; 2011
   Google Scholar
• China State Institute of Pharmaceutical Industry and Jiangsu Hengyi Pharmaceutical Co., Ltd. Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia. WO012121; 2010
   Google Scholar
• China State Institute of Pharmaceutical Industry and Jiangsu Hengyi Pharmaceutical Co., Ltd. Quinolinone derivatives and use thereof as medicament against schizophrenia. WO130153; 2012
   Google Scholar
• China State Institute of Pharmaceutical Industry and Zhejiang Huahai Pharmaceutical Co., Ltd. N-(Naphthoxyalkyl)heteroaryl piperidine compound and preparation method and application thereof. CN102161658; 2011
   Google Scholar
• Pfizer, Inc. (R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors. WO101774; 2011
   Google Scholar
• Brodney MA, Johnson DE, Sawant-Basak A, et al. Identification of multiple 5-HT(4) partial agonist clinical candidates for the treatment of Alzheimer’s disease. J Med Chem 2012;55:9240-54
   PubMed Web of Science ®Google Scholar
• A study to observe safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 in healthy adult and healthy elderly volunteers. ClinicalTrials.gov Web Site 2011. Available from: http://clinicaltrials.gov/show/NCT01169714 [Last accessed on 24 February 2015]
   Google Scholar
• A study to evaluate the safety, tolerability and plasma drug levels following a single dose of PF-04995274 in healthy adult volunteers. ClinicalTrials.gov Web Site 2010. Available from: http://clinicaltrials.gov/show/NCT01091272 [Last accessed on 24 February 2015]
   Google Scholar
• Nicholas T, Raunig D, Duvvuri S, et al. Pharmacokinetics, safety and tolerability of PF-04995274: a 5HT4 partial agonist being developed for the treatment of Alzheimer’s disease. Alzheimers Dement 2011;7:S786-7
   Google Scholar
• Sawant-Basak A, Coffman KJ, Walker GS, et al. Metabolism of a serotonin-4 receptor partial agonist 4-[4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): Identification of an unusual pharmacologically active cyclized oxazolidine metabolite in human. J Pharm Sci 2013;102:3277-93
   PubMed Web of Science ®Google Scholar
• Grimwood S, Drummond E, Zasadny K, et al. Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers. Alzheimers Dement 2011;7:S653
   Google Scholar
• To evaluate the relationship between plasma drug levels and receptor binding in brain using PET (Positron Emission Tomography) in healthy volunteers. ClinicalTrials.gov Web Site 2011. Available from: http://clinicaltrials.gov/show/NCT01173757 [Last accessed on 24 February 2015]
   Google Scholar
• Pfizer Web Site. 2011. Available from: http://www.pfizer.com/sites/default/files/product-pipeline/pipeline_2011_1110.pdf [Last accessed on 24 February 2015]
   Google Scholar
• Bach P, Isaac M, Slassi A. Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications. Expert Opin Ther Pat 2007;17:371-384
   Web of Science ®Google Scholar
• Wyeth LLC. Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5). WO124047; 2010
   Google Scholar
• Hughes ZA, Neal SJ, Smith DL, et al. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 2013;66:202-14
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators for anxiety/depression. WO143404; 2009
   Google Scholar
• Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations. Biochem Pharmacol 2011;82:915-30
   PubMed Web of Science ®Google Scholar
• Sumitomo Dainippon Pharma. Pyrimidine derivative. WO054634; 2014
   Google Scholar
• Sumitomo Dainippon Pharma Web Site. 2014. Available from: http://www.ds-pharma.com/pdf_view.php?id=400 [Last accessed on 24 February 2015]
   Google Scholar
• Lera RM, Lim Y-H, Zheng J. Adenosine A2A receptor as a drug discovery target. J Med Chem 2014;57:3623-50
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Agnati L, Fuxe K, et al. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 2006;29:647-54
   PubMed Web of Science ®Google Scholar
• Domain Therapeutics SA. New adenosine receptor ligands and uses thereof. WO084425; 2010
   Google Scholar
• Domain Therapeutics SA Web Site. 2014. Available from: http://www.domaintherapeutics.com/pipeline/pipeline.html [Last accessed on 24 February 2015]
   Google Scholar
• Domain Therapeutics SA Web Site. Available from: http://www.domaintherapeutics.com/files/novel-a2a-antagonists-flyer.pdf [Last accessed on 24 February 2015]
   Google Scholar
• Merck Sharp & Dohme Corp. Metabolites of 7-(2-(4-(6-fluoro-3-methylbenzo[d]isoxazol-5-yl)piperazin-1-yl)ethyl)-2-(prop-1-ynyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine and their utility as adenosine A2a receptor antagonists. WO135083; 2012
   Google Scholar
• Boss C. Orexin receptor antagonists - a patent review (2010 to August 2014). Expert Opin Ther Pat 2014;24:1367-81
   PubMed Web of Science ®Google Scholar
• FDA Web Site. 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm [Last accessed on 24 February 2015]
   Google Scholar
• Merck Sharp & Dohme. Isoxazolopyridine orexin receptor antagonists. WO062858; 2013
   Google Scholar
• Actelion Pharmaceuticals Ltd. 2-Aza-bicyclo[3.3.0]octane derivatives. WO016564; 2009
   Google Scholar
• Actelion Pharmaceuticals Ltd. Oxazolidine compounds as orexin receptor antagonists. WO038200; 2010
   Google Scholar
• Actelion Pharmaceuticals Ltd. Thiazolidine compounds as orexin receptor antagonists. WO004507; 2010
   Google Scholar
• Deng H. Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors. Expert Opin Drug Discov 2010;5:961-93
   PubMed Web of Science ®Google Scholar
• Keith JM, Apodaca R, Tichenor M, et al. Aryl piperazinyl ureas as inhibitors of fatty acid amide hydrolase (FAAH) in rat, dog, and primate. ACS Med Chem Lett 2012;3:823-7
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical NV. Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase. WO141809; 2010
   Google Scholar
• Gao L-J, Kovackova S, Sala M, et al. Discovery of dual death-associated protein related apoptosis inducing protein kinase 1 and 2 inhibitors by a scaffold hopping approach. J Med Chem 2014;57:7624-43
   PubMed Web of Science ®Google Scholar
• de Vicente J, Lemoine R, Bartlett M, et al. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines. Bioorg Med Chem Lett 2014;24:4969-75
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases. WO012312; 2009
   Google Scholar
• Ji Z, Dai Y, Abad-Zapatero C, et al. Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors. Bioorg Med Chem Lett 2012;22:4528-31
   PubMed Web of Science ®Google Scholar
• Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors. WO132774; 2009
   Google Scholar
• Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives. WO057757; 2011
   Google Scholar
• Eastwood P, Gonzalez J, Gomez E, et al. Indolin-2-one p38a inhibitors III: bioisosteric amide replacement. Bioorg Med Chem Lett 2011;21:6253-7
   PubMed Web of Science ®Google Scholar
• Gilead Calistoga LLC. Atropisomers of PI3K-inhibiting compounds. WO040634; 2012
   Google Scholar
• Takeda Pharmaceutical Company Ltd. Heterocyclic compounds and use thereof. WO028655; 2009
   Google Scholar
• Signal Pharmaceuticals LLC. Aminotriazolopyridines and their use as kinase inhibitors. WO027500; 2010
   Google Scholar
• AbbVie, Inc. Novel tricyclic compounds. US072470; 2013
   Google Scholar
• F. Hoffmann-La Roche AG. Indazole compounds, compositions and methods of use. WO024011; 2013
   Google Scholar
• Bristol-Myers Squib Co. Phthalazinones and isoquinolinones as ROCK inhibitors. WO113620; 2014
   Google Scholar
• BioEnergenix. Heterocyclic compounds for the inhibition of PASK. WO066795; 2014
   Google Scholar
• AstraZeneca. Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections. WO043893; 2010
   Google Scholar
• Basarab GS, Brassil P, Doig P, et al. Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization. J Med Chem 2014;57:9078-95
   PubMed Web of Science ®Google Scholar
• Randomized, open-label, phase II study of oral AZD-0914 in the treatment of gonorrhea (NCT02257918). ClinicalTrials.gov Web Site 2014. Available from: http://clinicaltrials.gov/show/NCT02257918 [Last accessed 24 February 2015]
   Google Scholar
• AstraZeneca’s novel antibiotic candidate AZD0914 given Fast Track status by US FDA. AstraZeneca Web Site 2014. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20140603--astrazenecas-novel-antibiotic-candidate-azd0914-fast-track-status [Last accessed 24 February 2015]
   Google Scholar
• University of Massachusetts. Compounds for modulating TLR2. WO062955; 2011
   Google Scholar
• Zhou S, Cerny AM, Bowen G, et al. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. Antiviral Res 2010;87:295-306
   PubMed Web of Science ®Google Scholar
• Xenon Pharmaceuticals, Inc. Biaryl ether sulfonamides and their use as therapeutic agents. WO064984; 2013
   Google Scholar
• Genentech, Inc. Xenon Pharmaceuticals, Inc. Substituted benzoxazoles and methods of use thereof. WO144545; 2014
   Google Scholar
• King GF, Vetter I. No gain, no pain: naV1.7 as an analgesic target. ACS Chem Neurosci 2014;5:749-51
   PubMed Web of Science ®Google Scholar
• Xenon Pharmaceuticals, Inc. Web Site 2014. Available from: http://www.xenon-pharma.com/product-candidates/pain/pain-genentech/ [Last accessed 24 February 2015]
   Google Scholar
• CalciMedica, Inc. Compounds that modulate intracellular calcium. WO027710; 2012
   Google Scholar
• CalciMedica, Inc. Web Site Available from: http://www.calcimedica.com/index.html [Last accessed 20 February 2015]
   Google Scholar
• N.V. Organon. 2-(1,2-Benzisoxazol-3-yl)benzylamine derivatives. WO003895; 2011
   Google Scholar
• Takasu K, Ono H, Tanabe M. Spinal hyperpolarization-activated cyclic nucleotide-gated cation channels at primary afferent terminals contribute to chronic pain. Pain 2010;151:87-96
   PubMed Web of Science ®Google Scholar
• Akzo Nobel N.V. Substituted benzylamine and their use for the treatment of depression. WO40027; 1997
   Google Scholar
• Akzo Nobel N.V. 2-(1,2-Benzisoxazol-3-yl)benzylamine derivatives. WO18941; 1999
   Google Scholar
• F. Hoffmann-La Roche AG. Benzisoxazole analogs as glycogen synthase activators. WO057956; 2011
   Google Scholar
• Uto Y. Benzisoxazole analogs as glycogen synthase activators, a patent evaluation (WO2011057956). Exp Opin Ther Pat 2012.22: 701-7
   Google Scholar
• Mitsubishi Tanabe Pharma Corp. Homocysteine synthase inhibitor. WO125853; 2009
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG. Substituted piperidino-dihydrothienopyrimidines. WO050248; 2009
   Google Scholar
• Actelion Pharmaceuticals Ltd. 1-Phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators. WO004722; 2012
   Google Scholar
• Leo Laboratories Ltd. 3-O-Heteroaryl-ingenol. WO001215; 2014
   Google Scholar
• Aldexa Therapeutics, Inc. Novel traps in the treatment of macular degeneration. WO116593; 2014
   Google Scholar
• Merck Patent GmbH and Cancer Research Technology Ltd. Azaheterocyclic compounds. WO110433; 2013
   Google Scholar
• Bristol-Myers Squibb Co. Substituted bicyclic heteroaryl compounds. WO049263; 2013
   Google Scholar
• Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor. WO043453; 2011
   Google Scholar
• Janssen Pharmaceutica NV. Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors. WO085954; 2013
   Google Scholar
• Boehringer Ingelheim International Gmbh. New indanyloxydihydrobenzofuranylacetic acids. WO082918; 2014
   Google Scholar
• F. Hoffmann-La Roche AG. Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists. WO050334; 2013
   Google Scholar
• Bristol-Myers Squibb Co. Lactam-containing compounds and derivatives thereof as factor Xa inhibitors. US201816; 2012
   Google Scholar
• Bristol-Myers Squibb Co. Lactam-containing compounds and derivatives thereof as factor Xa inhibitors. US212930; 2011
   Google Scholar
• Tianjin Institute of Pharmaceutical Research. Pradaxa derivative, preparation method and application thereof. CN103420983; 2013
   Google Scholar
• Tianjin International Joint Academy of Biotechnology and Medicine. An application of 3-(2-isobutoxy--5-(6-isobutoxy preparation method of -1,2-benzo)benzene)propionic acid compound and application thereof in medicine. CN103183646; 2013
   Google Scholar
• Merck Sharp & Dohme Corp. & Mochida Pharmaceutical Co., Ltd. Factor IXa inhibitors. WO120346; 2014
   Google Scholar
• Institute of Medicinal Biotechnology. Benzisoxazole substituted thiazole compounds, its preparation and application. CN102757426; 2012
   Google Scholar
• Bristol-Myers Squibb Co. Hepatitis C virus inhibitors. WO138488; 2010
   Google Scholar
• Janssen Pharmaceutica NV. Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B. WO033167; 2014
   Google Scholar
• Biota Scientific Management Pty. Ltd. Antiviral salts. WO143571; 2009
   Google Scholar
• Jiangsu Nhwa Pharmaceutical Co., Ltd. Benzisoxazole piperidinyl derivatives, pharmaceutical compositions comprising the derivatives and their use. WO072147; 2010
   Google Scholar